William Blair Investment Management LLC Acquires 162,469 Shares of Globus Medical, Inc. $GMED

William Blair Investment Management LLC boosted its holdings in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 12.6% in the third quarter, HoldingsChannel reports. The fund owned 1,447,365 shares of the medical device company’s stock after acquiring an additional 162,469 shares during the period. William Blair Investment Management LLC’s holdings in Globus Medical were worth $108,408,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Allworth Financial LP grew its holdings in Globus Medical by 3.5% in the third quarter. Allworth Financial LP now owns 12,797 shares of the medical device company’s stock worth $1,011,000 after purchasing an additional 436 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Globus Medical by 335.0% during the third quarter. Russell Investments Group Ltd. now owns 143,614 shares of the medical device company’s stock valued at $10,758,000 after purchasing an additional 110,602 shares in the last quarter. Maryland State Retirement & Pension System lifted its holdings in shares of Globus Medical by 14.7% during the third quarter. Maryland State Retirement & Pension System now owns 6,743 shares of the medical device company’s stock valued at $505,000 after purchasing an additional 863 shares during the last quarter. Jacobi Capital Management LLC purchased a new position in shares of Globus Medical during the third quarter valued at approximately $40,000. Finally, Illinois Municipal Retirement Fund lifted its holdings in shares of Globus Medical by 24.5% during the third quarter. Illinois Municipal Retirement Fund now owns 73,173 shares of the medical device company’s stock valued at $5,481,000 after purchasing an additional 14,412 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Performance

Shares of GMED stock opened at $72.02 on Monday. Globus Medical, Inc. has a one year low of $70.39 and a one year high of $101.40. The company’s 50-day moving average is $76.56 and its 200 day moving average is $82.71. The company has a market capitalization of $9.54 billion, a price-to-earnings ratio of 17.69, a price-to-earnings-growth ratio of 1.12 and a beta of 0.98.

Globus Medical (NYSE:GMED – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. The business had revenue of $763.72 million during the quarter, compared to analyst estimates of $792.39 million. Globus Medical had a net margin of 17.76% and a return on equity of 14.43%. Globus Medical’s revenue was down .7% compared to the same quarter last year. During the same period last year, the business earned $1.18 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, research analysts predict that Globus Medical, Inc. will post 4.98 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Stephen Zarrilli sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the sale, the director owned 25,000 shares in the company, valued at $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director James R. Tobin sold 41,666 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $75.16, for a total transaction of $3,131,616.56. Following the sale, the director directly owned 15,000 shares of the company’s stock, valued at $1,127,400. This trade represents a 73.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 101,666 shares of company stock worth $7,970,017 over the last 90 days. 18.38% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Needham & Company LLC dropped their price target on Globus Medical from $117.00 to $100.00 and set a “buy” rating on the stock in a research report on Friday, November 6th. Zacks Research lowered Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 9th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research report on Friday, October 9th. Truist Financial lowered their price objective on Globus Medical from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Monday, November 9th. Finally, Wells Fargo & Company boosted their target price on Globus Medical from $99.00 to $100.00 and gave the stock an “overweight” rating in a report on Friday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, Globus Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.08.

Read Our Latest Stock Report on Globus Medical

About Globus Medical

(Free Report)

Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.

Further Reading

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED – Free Report).

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.